

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 LOUISIANA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE NO.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY $^{a,\ b}$ NONDUAL BENEFICIARIES, LOUISIANA, 2005

			Number of	Beneficiar	ies			١	lumber of Be	enefit Month	S	
Beneficiary Characteristics	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	979,374	2,734	131,416	134,065	710,250	909	10,163,499	28,125	1,429,559	1,106,185	7,592,250	7,380
Age												
5 and younger	270,532	12	8,583	1	261,936	0	2,744,431	27	94,695	1	2,649,708	0
6-14	330,286	8	20,348	18	309,912	0	3,714,965	16	234,888	96	3,479,965	0
15-20	170,407	4	15,311	16,789	138,292	11	1,775,630	8	173,249	140,554	1,461,743	76
21-44	149,679	14	38,426	110,831	104	304	1,333,734	27	416,613	914,010	811	2,273
45-64	55,647	6	48,624	6,424	3	590	565,900	12	509,340	51,514	15	5,019
65-74	1,460	1,331	124	1	0	4	15,248	14,454	774	8	0	12
75-84	840	840	0	0	0	0	8,639	8,639	0	0	0	0
85 and older	520	519	0	1	0	0	4,944	4,942	0	2	0	0
Unknown	3	0	0	0	3	0	8	0	0	0	8	0
Gender												
Female	548,637	1,735	65,827	125,643	354,523	909	5,590,380	17,962	721,522	1,045,005	3,798,511	7,380
Male	430,613	983	65,586	8,416	355,628	0	4,571,919	10,023	708,012	61,142	3,792,742	0
Unknown	124	16	3	6	99	0	1,200	140	25	38	997	0
Race												
White	350,708	786	39,546	51,254	258,678	444	3,514,632	7,843	420,506	391,447	2,691,259	3,577
African American	556,504	1,371	76,412	74,320	403,986	415	5,936,730	14,527	840,060	655,926	4,422,802	3,415
Other/unknown	72,162	577	15,458	8,491	47,586	50	712,137	5,755	168,993	58,812	478,189	388
Use of Nursing Facilities ^c												
Entire year	2,453	604	1,845	2	2	0	25,268	6,016	19,212	16	24	0
Part year	1,617	272	1,335	5	4	1	15,622	2,758	12,769	38	48	9
None	975,304	1,858	128,236	134,058	710,244	908	10,122,609	19,351	1,397,578	1,106,131	7,592,178	7,371
Maintenance Assistance Statu	s											
Cash	306,437	1,840	125,124	72,775	106,698	0	3,243,152	20,280	1,373,640	676,667	1,172,565	0
Medically needy	2,232	2	218	1,490	522	0	22,820	24	1,610	15,180	6,006	0
Poverty-related	588,029	27	48	51,147	535,898	909	6,226,821	305	483	330,692	5,887,961	7,380
Other/unknown	82,676	865	6,026	8,653	67,132	0	670,706	7,516	53,826	83,646	525,718	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	979,374	2,734	131,416	134,065	710,250	909	10,163,499	28,125	1,429,559	1,106,185	7,592,250	7,380
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	Percentage with	Mean Number	Mara Du C	Ć D.	Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics All	at Least One Rx 67.3	of Rx		\$ per Rx		FFS \$ ^d	Beneficiaries 070 274
	67.3	8.6	\$567	\$66	\$2,563	22.1	979,374
Age	04.0	- 4	000	50	4 00 4	04.5	070 500
5 and younger	61.8	5.1	300	59		21.5	270,532
6-14	65.9	5.6	370	67	,	31.2	330,286
15-20	66.3	6.0	368	61	1,918	19.2	170,407
21-44	75.7	12.3	817	67	,	16.0	149,679
45-64	81.7	39.8	2,840	71	10,912	26.0	55,647
65-74	86.0	48.0	3,130	65	,	20.1	1,460
75-84	86.3	48.3	2,881	60	•	20.4	840
85 and older	88.8	49.0	3,047	62	,	17.3	520
Unknown	0.0	0.0	0	0	0	0.0	3
Basis of Eligibilitye							
Aged	85.5	48.5	3,044	63	15,415	19.7	2,734
Disabled	78.9	27.0	2,216	82	10,384	21.3	131,416
Adults	75.9	8.6	397	46	2,799	14.2	134,065
Children	63.4	5.0	280	56	1,003	27.9	710,250
Unknown	82.4	22.1	3,765	170	17,605	21.4	909
Gender							
Female	70.0	9.5	578	61	2,648	21.8	548,637
Male	63.8	7.4	552	75	2,455	22.5	430,613
Unknown	62.1	10.1	586	58	3,043	19.2	124
Race							
White	73.8	11.1	738	67	2,943	25.1	350,708
African American	63.4	6.9	441	64	2,257	19.6	556,504
Other/unknown	65.8	9.8	701	71	3,082	22.7	72,162
Use of Nursing Facili	ties ^f						
Entire year	95.8	88.5	6,701	76	45,956	14.6	2,453
Part year	98.0	63.6	5,085	80		9.6	1,617
None	67.2	8.3	544	66		22.9	975,304
Maintenance Assista					,		,
Cash	71.8	15.4	1,127	73	5,008	22.5	306,437
Medically needy	83.7	12.9	834	65	,	15.2	2,232
Poverty related	68.1	5.4	291	54	1,196	24.3	588,029
Other/unknown	44.2	6.4	447	70	3,153	14.2	82,676
5 IOI/ GITIGIOWIT	77.2	0.4	771	70	5,155	14.2	02,070

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving fost care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, LOUISIANA, 2005

				0.120712		nber of Rx, F	Percentage w	ith:			Numb	er
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.8	\$55	22.1	32.7	52.8	6.8	5.3	2.0	0.5	\$247	979,374	10,163,499
Age												
5 and younger	0.5	30	21.5	38.2	54.1	5.5	2.1	0.1	0.0	137	270,532	2,744,431
6-14	0.5	33	31.2	34.1	57.5	5.2	2.9	0.3	0.0	106	330,286	3,714,965
15-20	0.6	35	19.2	33.7	55.8	6.5	3.4	0.5	0.0	184	170,407	1,775,630
21-44	1.4	92	16.0	24.3	49.8	11.3	10.6	3.5	0.5	573	149,679	1,333,734
45-64	3.9	279	26.0	18.3	19.0	11.4	25.6	19.9	5.7	1,073	55,647	565,900
65-74	4.6	300	20.1	14.0	14.2	10.0	27.7	25.0	9.0	1,488	1,460	15,248
75-84	4.7	280	20.4	13.7	11.9	9.8	29.4	27.1	8.1	1,371	840	8,639
85 and older	5.2	321	17.3	11.2	10.4	10.6	27.5	31.2	9.2	1,851	520	4,944
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	3	8
Basis of Eligibility	/ ^e											
Aged	4.7	296	19.7	14.5	12.7	10.1	27.7	26.3	8.7	1,499	2,734	28,125
Disabled	2.5	204	21.3	21.1	34.0	11.5	18.9	11.5	3.0	955	131,416	1,429,559
Adults	1.0	48	14.2	24.1	55.4	11.0	7.7	1.7	0.1	339	134,065	1,106,185
Children	0.5	26	27.9	36.6	55.9	5.1	2.2	0.2	0.0	94	710,250	7,592,250
Unknown	2.7	464	21.4	17.6	26.8	18.3	27.2	9.2	0.9	2,169	909	7,380
Gender												
Female	0.9	57	21.8	30.0	53.8	7.4	5.9	2.4	0.6	260	548,637	5,590,380
Male	0.7	52	22.5	36.2	51.5	6.1	4.6	1.4	0.3	231	430,613	4,571,919
Unknown	1.0	61	19.2	37.9	45.2	4.0	5.6	6.5	0.8	315	124	1,200
Race												
White	1.1	74	25.1	26.2	53.8	9.2	7.4	2.7	0.7	294	350,708	3,514,632
African American	0.6	41	19.6	36.6	52.5	5.2	4.0	1.4	0.3	212	556,504	5,936,730
Other/unknown	1.0	71	22.7	34.2	49.5	6.8	6.0	2.8	0.7	312	72,162	712,137
Use of Nursing Fa	cilities ^f											
Entire year	8.6	651	14.6	4.2	2.0	2.9	19.3	41.3	30.3	4,461	2,453	25,268
Part year	6.6	526	9.6	2.0	7.6	8.7	28.3	36.9	16.5	5,492	1,617	15,622
None	0.8	52	22.9	32.8	53.0	6.8	5.3	1.8	0.3	228	975,304	10,122,609
Maintenance Assi	stance Status	5										
Cash	1.5	106	22.5	28.2	45.5	8.9	10.8	5.4	1.3	473	306,437	3,243,152
Medically needy	1.3	82	15.2	16.3	56.9	11.4	11.1	3.9	0.4	536	2,232	22,820
Poverty related	0.5	28	24.3	31.9	59.4	5.9	2.6	0.2	0.0	113	588,029	6,226,821
Other/unknown	0.8	55	14.2	55.8	32.2	5.2	4.5	1.8	0.6	389	82,676	670,706

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{A, b, c}

NONDUAL BENEFICIARIES, LOUISIANA, 2005

		All Rx		Patented	d Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	d-Name	Gen	eric D	ruas
Beneficiary	Number	7 11 1 100		Number	Drago		Number	Diago		Number	one B	ugo
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	0.8	\$55	\$66	0.3	\$40	\$120	0.1	\$4	\$60	0.4	\$11	\$2
Age												
5 and younger	0.5	30	59	0.2	22	113	0.1	2	33	0.2	5	22
6-14	0.5	33	67	0.2	25	104	0.0	2	57	0.2	5	25
15-20	0.6	35	61	0.2	26	112	0.0	3	57	0.3	7	23
21-44	1.4	92	67	0.5	65	140	0.1	6	81	0.8	21	2
45-64	3.9	279	71	1.5	202	132	0.2	15	89	2.2	62	28
65-74	4.6	300	65	1.9	221	118	0.2	9	53	2.6	70	27
75-84	4.7	280	60	1.9	202	107	0.2	11	47	2.6	67	26
85 and older	5.2	321	62	2.0	204	102	0.3	36	125	2.9	80	28
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Basis of Eligibility	d											
Aged	4.7	296	63	1.9	211	112	0.2	14	68	2.6	71	2
Disabled	2.5	204	82	1.0	154	154	0.1	11	88	1.4	38	2
Adults	1.0	48	46	0.3	30	94	0.1	4	66	0.7	14	2
Children	0.5	26	56	0.2	19	94	0.0	2	44	0.2	5	23
Unknown	2.7	464	170	0.9	400	436	0.1	13	146	1.7	52	30
Gender												
Female	0.9	57	61	0.4	41	113	0.1	4	58	0.5	13	24
Male	0.7	52	75	0.3	40	130	0.1	3	62	0.3	9	2
Unknown	1.0	61	58	0.4	40	107	0.1	4	49	0.6	17	28
Race												
White	1.1	74	67	0.5	54	117	0.1	5	63	0.6	15	20
African American	0.6	41	64	0.2	30	122	0.0	3	56	0.3	8	2
Other/unknown	1.0	71	71	0.4	53	128	0.1	4	63	0.5	14	2
Use of Nursing Fa	cilities ^e											
Entire year	8.6	651	76	3.3	472	144	0.3	21	61	4.9	156	32
Part year	6.6	526	80	2.4	361	153	0.3	31	106	3.9	134	3-
None	0.8	52	66	0.3	39	119	0.1	3	59	0.4	10	2
Maintenance Assi	stance Sta	tus										
Cash	1.5	106	73	0.6	79	140	0.1	6	76	0.8	21	2
Medically needy	1.3	82	65	0.4	56	140	0.1	5	75	0.8	20	2
Poverty related	0.5	28	54	0.2	20	92	0.0	2	45	0.2	6	2
Other/unknown	0.8	55	70	0.3	42	127	0.1	3	56	0.4	10	2

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Louisiana, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, LOUISIANA, 2005

		nber of R Month Am			\$ per	Benefit N Us	Month Amers	nong		\$ per	·Rx					Userse	
Therapeutic Category	F Total	Patented Brand- Name	Brand-	Seneric		atented Brand- Name		Seneric	F Total	Patented Brand- Name	Brand-	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.1	0.0	0.1	\$13	\$8	\$2	\$4	\$55	\$111	\$63	\$26	1,266,731	\$69,775,524	470,454	48.0	5,276,209
Biologicals	0.4	0.4	0.0	0.0	639	614	16	9	1498	1,481	1,865	2,451	15,990	23,949,408	3,582	0.4	37,460
Antineoplastic Agents	0.4	0.1	0.0	0.3	131	98	3	30	296	793	422	95	16,108	4,762,053	3,385	0.3	36,274
Endocrine/Metabolic Drugs	0.3	0.1	0.0	0.2	19	12	3	5	56	96	61	26	631,857	35,672,134	168,273	17.2	1,855,872
Cardiovascular Agents	1.0	0.4	0.0	0.6	47	34	1	13	46	80	47	22	845,105	38,696,465	74,937	7.7	818,997
Respiratory Agents	0.4	0.2	0.0	0.1	19	16	1	2	53	79	29	20	1,581,404	84,385,529	383,709	39.2	4,354,479
Gastrointestinal Agents	0.3	0.2	0.0	0.1	34	31	0	3	100	152	56	24	343,251	34,235,168	90,562	9.2	998,736
Genitourinary Agents	0.2	0.1	0.0	0.1	11	7	1	3	52	76	62	29	100,055	5,245,500	45,101	4.6	472,374
CNS Drugs	0.6	0.3	0.0	0.3	62	53	1	8	95	173	123	25	859,312	81,994,253	119,957	12.2	1,326,335
Stimulants/Anti-obesity/Anorexia	0.5	0.5	0.0	0.1	53	50	1	2	99	107	74	42	324,404	32,151,882	52,935	5.4	610,876
Miscellaneous Psychological/ Neurological Agents Analgesics and Anesthetics	0.4	0.3	0.0	0.1 0.3	99 13	93 5	0	5 6	240 40	288 145	118 177	64 21	13,899 967,647	3,342,002 38,240,139	3,026 274,981	0.3 28.1	33,646 3,030,289
Neuromuscular Agents	0.6	0.2	0.0	0.3	43	27	3	13	78	151	91	38	420,003	32,608,428	68,425	7.0	759,932
Nutritional Products	0.2	0.1	0.0	0.2	5	2	0	3	23	34	24	20	209,941	4,899,735	85,192		892,994
Hematological Agents	0.4	0.2	0.0	0.2	77	72	1	4	203	430	30	22	123,728	25,069,751	31,466	3.2	326,404
Topical Products	0.2	0.1	0.0	0.1	11	7	0	3	53	84	48	30	649.459	34,132,346	279.345	28.5	3,189,588
Miscellaneous Products	0.2	0.1	0.0	0.1	28	18	4	6	147	176	409	76	37,338	5,490,169	17,429	1.8	199,259
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	5	0	0	0	30	0	0	0	14,797	446,586	7,738	0.8	87,395
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8,421,029	555,097,072	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Louisiana, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	-		Users		An	nong Usei	S
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$52,539,753	39,367	4.0	450,176	0.5	\$234	\$117
ANTIASTHMATIC	45,791,591	237,570	24.3	2,724,809	0.2	77	17
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	32,151,882	63,657	6.5	737,174	0.4	99	44
ANTICONVULSANT	26,698,135	38,143	3.9	429,249	0.6	111	62
ULCER DRUGS	25,872,257	74,189	7.6	822,067	0.3	109	31
DERMATOLOGICAL	24,012,150	281,420	28.7	3,237,781	0.1	56	7
PASSIVE IMMUNIZING AGENTS	22,914,927	3,406	0.3	35,596	0.4	1,455	644
ANTIDEPRESSANTS	21,613,730	81,924	8.4	902,185	0.4	63	24
ANALGESICS - Narcotic	20,168,754	258,880	26.4	2,827,853	0.2	33	7
ANTIHISTAMINES	19,148,228	269,346	27.5	3,090,407	0.2	38	6
Total	290,911,407	1,347,902		15,257,297	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

⁼ Medicaid reimbursement.

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	All Top 1	0 Drug Groups		ANTI	PSYCHOTIC	CS			Al	NTIASTHMA	TIC	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit I Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	3,515,033	\$290,911,407	39,367	4.0	450,176	0.5	\$117	237,570	24.3	2,724,809	0.2	\$17
Female												
All Females	2,019,036	154,188,670	20,394	3.7	231,650	0.5	109	121,250	22.1	1,382,592	0.2	16
Female, Disabled												
All Ages	884,385	83,422,195	14,189	21.6	163,693	0.5	130	29,066	44.2	333,750	0.3	24
5 and younger	19,602	5,558,585	32	0.9	366	0.4	85	2,174	61.9	25,142	0.2	21
6-14	45,621	4,675,520	697	10.6	8,184	0.4	87	2,500	37.9	29,458	0.3	26
15-20	38,470	3,868,437	898	15.6	10,480	0.4	92	1,457	25.3	17,043	0.3	20
21-44	248,915	23,552,474	5,267	26.0	60,867	0.5	129	6,526	32.2	75,140	0.3	18
45-64	531,110	45,705,639	7,279	24.6	83,656	0.6	139	16,378	55.3	186,817	0.4	26
65-74	667	61,540	16	21.6	140	0.7	154	31	41.9	150	0.4	34
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	1,134,651	70,766,475	6,205	1.3	67,957	0.3	59	92,184	19.1	1,048,842	0.2	14
5 and younger	221,459	16,697,980	94	0.1	1,099	0.3	51	31,939	24.8	367,924	0.2	14
6-14	348,778	23,639,971	1,447	0.9	16,948	0.4	72	34,071	21.9	398,706	0.2	15
15-20	193,313	11,052,713	1,549	1.8	17,315	0.3	54	13,024	15.0	147,273	0.2	13
21-44	314,271	15,474,271	2,483	2.4	25,948	0.3	46	11,330	10.8	115,827	0.2	11
45-64	32,977	2,064,692	263	4.9	2,655	0.3	45	1,181	22.0	12,122	0.3	17
65-74	13,238	1,108,046	200	22.7	2,223	0.7	144	354	40.1	3,941	0.4	28
75-84	6,458	464,655	96	18.7	1,026	0.7	100	173	33.7	1,858	0.4	26
85 and older	4,157	264,147	73	23.0	743	0.6	57	112	35.2	1,191	0.4	21
Male												
All Males	1,495,563	136,695,383	18,964	4.4	218,443	0.5	125	116,292	27.0	1,341,909	0.2	17
Male, Disabled												
All Ages	576,657	65,384,247	13,118	20.0	151,249	0.6	145	19,980	30.5	228,331	0.3	23
5 and younger	30,547	7,114,349	141	2.8	1,652	0.4	73	3,772	74.4	43,727	0.2	23
6-14	112,010	11,490,379	2,487	18.1	29,097	0.5	98	5,452	39.6	63,877	0.3	23
15-20	58,241	6,798,114	1,842	19.3	21,650	0.5	121	2,123	22.3	24,838	0.3	21
21-44	156,202	19,072,777	4,745	26.1	54,664	0.6	172	2,617	14.4	29,466	0.3	19
45-64	219,331	20,878,358	3,897	20.5	44,162	0.6	156	5,988	31.5	66,238	0.4	27
65-74	326	30,270	6	12.0	24	1.0	374	28	56.0	185	0.4	30
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	All Top 10	Drug Groups		ANTI	PSYCHOTIC	S			1A	NTIASTHMA	ΓIC	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	918,906	71,311,136	5,846	1.6	67,194	0.4	81	96,312	26.4	1,113,578	0.2	16
5 and younger	258,832	21,005,995	292	0.2	3,430	0.4	57	41,872	31.4	481,754	0.2	15
6-14	483,219	37,155,083	3,520	2.3	41,359	0.4	81	43,043	27.8	503,428	0.2	17
15-20	133,355	10,052,157	1,587	2.3	17,857	0.4	79	10,222	14.9	116,641	0.2	15
21-44	22,270	1,492,218	172	2.8	1,639	0.3	67	521	8.6	4,978	0.2	11
45-64	6,776	457,394	23	1.4	224	0.3	70	267	16.1	2,575	0.3	21
65-74	6,991	600,127	110	24.5	1,236	0.9	160	175	39.0	1,945	0.5	32
75-84	4,453	316,812	89	27.7	918	0.6	87	118	36.8	1,267	0.3	21
85 and older	3,010	231,350	53	26.9	531	0.6	82	94	47.7	990	0.4	23
Unknown	434	27,354	9	7.1	83	0.6	104	28	22.0	308	0.2	12

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

ULCER DRUGS STIMULANTS/ANTI-OBESITY/ANOREXIANTS ANTICONVULSANT Number of Number of Mean Number of Mean Mean Users Benefit Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean as % Rx per Rx \$ per as % Rx per Rx \$ per as % Months Rx per Rx \$ per Months Months Benefit Benefit Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of of All Among **Beneficiary Characteristics** Users Benes Month Users Benes Users Month Month Benes Users Month Month Users Users Month ΑII 63.657 6.5 737.174 0.4 \$44 38.143 3.9 429,249 0.6 \$62 74.189 7.6 822.067 0.3 \$32 Female All Females 19,994 3.6 230,314 0.4 41 22,882 4.2 256,506 0.5 58 50,062 9.1 553,906 0.3 32 Female, Disabled All Ages 3,928 6.0 45,851 0.4 43 14,994 22.8 171,631 0.6 68 21,092 32.0 241,892 0.4 51 74 5 and younger 114 3.2 1,256 0.4 59 205 5.8 2,292 0.6 529 15.1 5,714 0.3 21 44 39 6-14 1,630 24.7 19,102 0.4 924 14.0 10,839 0.7 111 546 8.3 6,437 0.4 15-20 502 8.7 5.886 0.4 44 967 16.8 11.309 0.7 100 720 12.5 8.410 0.3 26 21-44 746 3.7 8,627 0.2 34 5,203 25.7 59,757 0.6 73 5,566 27.5 64,234 0.4 41 45-64 932 3.1 10,939 0.3 45 7,686 25.9 87,359 0.6 55 13,699 46.2 156,860 0.5 57 41 65-74 4 5.4 41 0.4 45 9 12.2 75 0.5 32 43.2 237 0.5 65 0 75-84 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 0 0.0 0 0 85 and older 0 0.0 0 0.0 0 0 0.0 0 0.0 0.0 0 0.0 0 Female, Other Eligibles All Ages 16,066 3.3 184,463 0.4 41 7,888 1.6 84,875 0.4 38 28,970 6.0 312,014 0.2 18 702 0.5 8,060 0.3 28 232 2,598 0.4 48 38,202 9 0.2 3,695 2.9 0.2 5 and younger 6-14 11.362 7.3 132.012 0.5 43 0.8 15,288 0.4 55 75,338 0.1 13 1.314 6,419 4.1 15-20 2,506 2.9 28,282 0.4 40 1,483 1.7 16,397 0.4 44 6,513 7.5 72,954 0.2 15 21-44 1,388 1.3 15,004 0.2 27 4,135 3.9 42,902 0.3 28 10,379 9.9 104,749 0.2 22 45-64 97 1.8 979 0.3 40 449 8.4 4,639 0.4 36 1,185 22.1 12,203 0.3 41 65-74 7 0.8 84 0.2 39 173 19.6 1.971 0.7 48 404 45.8 4.578 0.5 62 75-84 36 102 13.5 746 46 2,543 53 3 0.6 0.5 69 0.6 233 45.4 0.5 1 0.3 6 1.0 75 33 10.4 334 0.8 39 142 61 85 and older 44.7 1,447 0.6 Male All Males 43,659 506,816 15,256 172,698 69 268,070 0.3 30 10.1 0.5 45 3.5 0.6 24,119 5.6 Male, Disabled All Ages 8,459 12.9 10,968 10,334 47 98,999 0.5 48 16.7 124,622 0.7 77 15.8 115,248 0.4 6.7 36 290 0.6 84 567 6,214 20 5 and younger 338 3.966 0.3 5.7 3,356 11.2 0.3 6-14 6,144 44.7 71,907 0.5 49 1,816 13.2 21,236 0.6 80 903 6.6 10,530 0.3 33 15-20 1,537 16.1 18,097 0.4 48 1,311 13.7 15,350 0.7 97 692 7.3 8,105 0.3 36 21-44 272 1.5 46 3.842 43.602 88 2.760 31.060 47 3.132 0.4 21.1 0.7 15.2 0.4 45-64 168 0.9 1,897 0.3 43 3,698 19.5 41,023 0.6 55 5,399 28.4 59,239 0.5 55 65-74 0 0.0 0 0.0 0 11 22.0 55 0.6 41 13 26.0 100 0.6 84 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 85 and older 0 0.0 0 0 0 0.0 0 0.0 0.0

TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	STIMULA	NTS/ANT	I-OBESITY//	ANOREXIA	ANTS		ANTI	CONVULSAN	NT			UL	CER DRUGS		
		I	Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	Number of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months	Rx per I	Rx \$ per		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per l	Rx \$ per
Description Of the state of	Number of	of All	Among	Benefit		Number of	of All	Among			Number of	of All	Among		Benefit
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Eligibles															
All Ages	35,200	9.6	407,817	0.5	44	4,288	1.2	48,076	0.4	47	13,785	3.8	152,822	0.2	16
5 and younger	1,832	1.4	21,307	0.3	27	356	0.3	4,101	0.4	43	4,104	3.1	42,746	0.2	9
6-14	28,425	18.4	330,190	0.5	45	2,069	1.3	24,095	0.4	48	5,471	3.5	64,073	0.2	14
15-20	4,874	7.1	55,666	0.4	44	1,117	1.6	12,421	0.4	52	2,992	4.4	33,996	0.2	17
21-44	52	0.9	479	0.3	34	432	7.1	4,245	0.4	36	598	9.8	5,652	0.3	39
45-64	9	0.5	94	0.2	21	135	8.1	1,218	0.4	34	241	14.5	2,253	0.4	49
65-74	3	0.7	27	0.3	58	98	21.8	1,089	0.8	61	167	37.2	1,880	0.6	65
75-84	4	1.2	42	0.3	27	57	17.8	664	0.6	37	130	40.5	1,395	0.6	60
85 and older	1	0.5	12	0.3	48	24	12.2	243	0.7	36	82	41.6	827	0.7	79
Unknown	4	3.1	44	0.7	60	5	3.9	45	0.4	13	8	6.3	91	0.3	25

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

		DERI	MATOLOGIC	AL				MMUNIZING				ANTI	DEPRESSA	NTS	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Jumber of Rx per Benefit Month		Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users			Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Benefit	Mean Rx \$ per Benefit Month
All	281,420	28.7	3,237,781	0.1	\$7	3,406	0.3	35,596	0.4	\$644	81,924	8.4	902,185	0.4	\$24
Female															
All Females	160,083	29.2	1,834,695	0.1	8	1,761	0.3	18,314	0.4	585	59,067	10.8	644,487	0.4	24
Female, Disabled	ł														
All Ages	24,216	36.8	280,998	0.2	10	619	0.9	6,706	0.5	752	28,344	43.1	324,163	0.5	29
5 and younger	1,934	55.0	22,437	0.1	7	593	16.9	6,398	0.5	684	19	0.5	220	0.3	8
6-14	2,742	41.6	32,272	0.1	9	10	0.2	120	0.8	1,285	686	10.4	8,026	0.4	23
15-20	1,976	34.2	23,290	0.1	8	6	0.1	70	1.1	2,327	1,326	23.0	15,544	0.4	23
21-44	6,393	31.6	74,681	0.2	9	7	0.0	83	0.4	1,109	9,349	46.2	107,324	0.4	27
45-64	11,151	37.6	128,183	0.2	12	3	0.0	35	1.1	7,451	16,944	57.2	192,895	0.5	31
65-74	20	27.0	135	0.3	20	0	0.0	0	0.0	0	20	27.0	154	0.6	32
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other El	igibles														
All Ages	135,867	28.1	1,553,697	0.1	7	1,142	0.2	11,608	0.4	488	30,723	6.4	320,324	0.3	19
5 and younger	51,462	40.0	591,498	0.1	6	805	0.6	8,450	0.4	631	121	0.1	1,416	0.2	. 7
6-14	47,476	30.6	558,697	0.1	8	8	0.0	96	0.5	1,095	3,608	2.3	42,084	0.3	18
15-20	20,144	23.2	229,488	0.1	8	92	0.1	938	0.1	20	7,204	8.3	79,110	0.3	18
21-44	14,983	14.2	154,496	0.1	8	237	0.2	2,124	0.1	95	17,521	16.7	174,589	0.3	19
45-64	1,063	19.8	11,298	0.2	9	0	0.0	0	0.0	0	1,730	32.3	17,211	0.4	21
65-74	318	36.1	3,658	0.2	14	0	0.0	0	0.0	0	298	33.8	3,295	0.6	34
75-84	251	48.9	2,724	0.2	12	0	0.0	0	0.0	0	142	27.7	1,533	0.6	33
85 and older	170	53.5	1,838	0.2	12	0	0.0	0	0.0	0	99	31.1	1,086	0.7	40
Male															
All Males	121,293	28.2	1,402,638	0.1	7	1,645	0.4	17,282	0.5	707	22,848	5.3	257,622	0.4	24
Male, Disabled															
All Ages	18,535	28.3	213,802	0.2	10	681	1.0	7,346	0.5	736	12,780	19.5	144,384	0.4	27
5 and younger	2,976	58.7	34,714	0.1	7	655	12.9	7,037	0.5	714	52	1.0	600	0.4	18
6-14	4,752	34.5	55,897	0.1	7	18	0.1	213	0.8	1,224	1,824	13.3	21,322	0.4	22
15-20	2,134	22.4	25,036	0.1	8	5	0.1	60	0.6	1,075	1,584	16.6	18,472	0.4	24
21-44	3,798	20.9	43,548	0.2	11	3	0.0	36	0.6	1,510	4,062	22.4	45,850	0.5	30
45-64	4,868	25.6	54,544	0.2	13	0	0.0	0	0.0	0	5,249	27.6	58,107	0.5	28
65-74	7	14.0	63	0.2	11	0	0.0	0	0.0	0	9	18.0	33	0.6	40
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

		DERM	MATOLOGIC	AL				MUNIZING A				ANTI	DEPRESSAN	NTS	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N		Mean		Users		lumber of	Mean		Users		Number of	Mean
Danefisian	Niconstruct	as %	Months		Rx \$ per	Ni	as %	Months	Rx per I		Nissan and	as %			Rx \$ per
Beneficiary Characteristics	Number of Users	of All Benes	Among Users	Benefit Month		Number of Users	of All Benes	Among Users	Benefit Month	Month	Number of Users	of All Benes	- 3	Benefit Month	Benefit Month
Male, Other Elig	ibles														
All Ages	102,758	28.2	1,188,836	0.1	7	964	0.3	9,936	0.4	685	10,068	2.8	113,238	0.3	20
5 and younger	49,007	36.8	562,233	0.1	6	954	0.7	9,816	0.4	677	187	0.1	2,191	0.3	8
6-14	40,597	26.3	477,791	0.1	6	8	0.0	96	0.6	1,428	5,029	3.3	58,898	0.3	19
15-20	11,818	17.3	135,312	0.1	9	2	0.0	24	0.7	852	3,238	4.7	36,277	0.3	21
21-44	629	10.3	6,057	0.2	11	0	0.0	0	0.0	0	991	16.3	9,555	0.3	20
45-64	202	12.2	1,940	0.2	9	0	0.0	0	0.0	0	309	18.6	2,928	0.3	22
65-74	189	42.1	2,123	0.3	17	0	0.0	0	0.0	0	135	30.1	1,492	0.6	38
75-84	168	52.3	1,814	0.2	12	0	0.0	0	0.0	0	98	30.5	1,027	0.7	43
85 and older	148	75.1	1,566	0.2	17	0	0.0	0	0.0	0	81	41.1	870	0.7	47
Unknown	44	34.6	448	0.1	9	0	0.0	0	0.0	0	9	7.1	76	0.4	27

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

ANALGESICS - Narcotic ANTIHISTAMINES Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean Rx per Rx \$ per as % Months as % Months Rx per Rx \$ per Beneficiary Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of Number of Characteristics Benes Users Beneficiaries Benefit Months Users Users Month Month Benes Users Month Month ΑII 258.880 26.4 2.827.853 0.2 \$7 269.346 27.5 3.090.407 0.2 \$6 979.374 10.163.499 Female All Females 182,792 33.3 1,966,195 0.2 7 153,044 27.9 1,739,065 0.2 6 548,636 5,590,377 Female, Disabled All Ages 47,312 71.9 542,291 0.3 15 25,199 38.3 292,338 0.3 10 65,827 721,522 490 0.1 3 5 and younger 13.9 5,757 1,640 46.7 19,102 0.2 4 3,514 38,289 2 6-14 1,094 16.6 12,996 0.1 2,451 37.2 28,990 0.2 8 6,588 76,091 15-20 2.100 36.4 24.640 0.2 3 1.812 31.4 21.296 0.2 8 5.770 65.667 20,252 21-44 16,278 80.4 187,241 0.3 14 7,195 35.5 83,512 0.2 9 223,574 45-64 27,304 92.2 311,301 0.4 17 12,080 40.8 139,228 0.3 13 29,629 317,400 46 65-74 62.2 356 0.4 10 21 28.4 210 0.3 17 74 501 0 0 75-84 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0 85 and older 0.0 0 0.0 0 0.0 0.0 0 0 0 Female, Other Eligibles All Ages 135,480 28.1 1,423,904 0.2 4 127,845 26.5 1,446,727 0.1 5 482,809 4,868,855 9,667 7.5 112,993 0.1 38,117 29.6 0.1 1 441,748 4 128,635 1,301,541 5 and younger 19,559 12.6 229,297 0.1 1 45,393 29.2 533,569 0.1 6 1,744,551 6-14 155,265 15-20 32,137 37.1 349,648 0.1 2 21,765 25.1 244,212 0.1 6 86,677 886,701 21-44 69,656 66.2 685,378 0.2 5 20,629 19.6 206,651 0.2 5 105,158 872,968 45-64 3,433 64.0 35,118 0.3 12 1,362 25.4 14,199 0.2 9 5,361 45,177 65-74 580 65.8 6.566 0.4 13 323 36.6 3.581 0.3 13 882 9,581 75-84 289 3,182 0.3 12 32.6 12 513 56.3 167 1,824 0.3 5,280 85 and older 159 50.0 1.722 0.4 11 89 28.0 943 0.3 13 318 3,056 Male All Males 76,061 861,374 116,263 27.0 1,350,912 0.2 6 430,611 4,571,914 17.7 0.2 8 Male. Disabled All Ages 25,480 38.8 285,311 16,770 0.2 9 65,586 708,012 0.3 18 25.6 194,538 749 14.8 8,852 0.1 2,456 48.5 0.2 5,069 56,406 5 and younger 1 28,806 5 6-14 2,033 14.8 24,029 0.1 2 4,983 36.2 58,764 0.2 8 13,760 158,797 15-20 2,325 24.4 27,190 0.2 3 2,107 22.1 24,782 0.2 9 9,541 107,582 21-44 7,879 43.4 88.174 3.300 18.2 37,950 18.173 193,027 0.3 16 0.3 11 45-64 12,472 65.7 136,924 0.4 27 3,912 20.6 44,146 0.3 12 18,993 191,927 65-74 22 44.0 142 0.5 16 12 24.0 90 0.3 10 50 273 75-84 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 0 0.0 0 0 85 and older 0 0.0 0 0.0 0 0 0.0 0

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, LOUISIANA, 2005

		ANAL	GESICS - Nard	cotic			ANT	THISTAMINE	S			
			Number of	Mean				Number of	Mean			
		Users		lumber of	Mean		Users		lumber of	Mean		
D " ·		as %			Rx \$ per		as %	Months		Rx \$ per		
Beneficiary	Number of	of All	- 3	Benefit	Benefit	Number of	of All	Among	Benefit		Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries E	senetit Months
Male, Other Elig	ibles											
All Ages	50,581	13.9	576,063	0.1	3	99,493	27.3	1,156,374	0.1	6	365,025	3,863,902
5 and younger	11,857	8.9	138,395	0.1	1	41,282	31.0	478,428	0.1	4	133,262	1,347,683
6-14	19,927	12.9	233,756	0.1	1	45,625	29.5	535,221	0.2	7	154,634	1,735,123
15-20	14,343	21.0	161,031	0.1	2	11,617	17.0	132,884	0.1	7	68,411	715,598
21-44	3,190	52.4	30,096	0.4	22	521	8.6	5,062	0.2	7	6,089	44,115
45-64	809	48.7	7,850	0.4	18	160	9.6	1,518	0.2	9	1,662	11,383
65-74	210	46.8	2,363	0.4	15	124	27.6	1,417	0.3	14	449	4,856
75-84	156	48.6	1,714	0.4	10	104	32.4	1,185	0.4	16	321	3,291
85 and older	89	45.2	858	0.4	17	60	30.5	659	0.4	15	197	1,853
Unknown	27	21.3	284	0.3	4	39	30.7	430	0.2	6	127	1.208

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC^{a, b}

NONDUAL BENEFICIARIES, LOUISIANA, 2005

Deneficient		Number of Dynas Deposit	Number of All Veer Number	Benefit Months Among All-
Beneficiary Characteristics	Rx \$ per Benefit Month	Month	Number of All-Year Nursing Facility Residents	Year Nursing Facility Residents
All	\$651	8.6		25,268
Age				
0-64	705	8.9	1,832	19,155
65-74	584	8.2	230	2,391
75-84	436	7.7	189	1,817
85 and older	390	6.8	202	1,905
Unknown	0	0.0	0	0
Gender				
Female	695	9.3	1,240	12,999
Male	604	7.8	1,206	12,224
Unknown	495	7.6	7	45
Race				
White	670	9.2	1,043	10,948
African American	628	8	1,159	11,964
Other/unknown	679	8.5	251	2,356
Basis of Eligibility	:			
Aged	477	7.7	604	6,016
Disabled	704	8.9	1,845	19,212
Adults	476	7.6	2	16
Children	1,534	11.5	2	24
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e} NONDUAL BENEFICIARIES, LOUISIANA, 2005

Number of Rx per Benefit \$ per Benefit Month Among

Month Among Users \$ per Rx

Therapeutic Category	P Total	atented Brand- Name	Off- Patent Brand- Name (Generic		atented Brand- Name	Off- Patent Brand- Name G	eneric	F Total	Patented Brand- Name		Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.2	0.0	0.3	\$61	\$45	\$5	\$10	\$130	\$280	\$115	\$39	8,190	\$1,065,075	1,646	67.1	17,559
Biologicals	0.2	0.2	0.0	0.0	367	367	0	0	1651	1,651	0	0	14	23,111	6	0.2	63
Antineoplastic Agents	0.6	0.0	0.0	0.5	83	17	0	66	150	822	144	125	1,341	201,222	237	9.7	2,419
Endocrine/Metabolic Drugs	1.2	0.5	0.2	0.6	74	54	7	13	60	110	39	23	15,034	901,381	1,156	47.1	12,175
Cardiovascular Agents	2.1	0.6	0.0	1.5	85	49	1	35	40	80	33	23	40,625	1,612,577	1,812	73.9	18,969
Respiratory Agents	0.9	0.4	0.0	0.4	47	37	1	9	52	84	29	21	12,690	655,904	1,297	52.9	13,956
Gastrointestinal Agents	1.2	0.5	0.0	0.6	92	74	1	17	77	136	58	27	19,765	1,524,212	1,573	64.1	16,543
Genitourinary Agents	0.7	0.4	0.0	0.3	51	36	2	13	70	87	89	45	4,787	336,083	598	24.4	6,560
CNS Drugs	2.0	1.1	0.0	0.9	242	210	1	31	122	192	84	35	40,784	4,961,927	1,910	77.9	20,467
Stimulants/Anti-obesity/Anorexia	0.6	0.4	0.0	0.2	77	73	0	4	133	170	0	28	231	30,755	37	1.5	399
Miscellaneous Psychological/ Neurological Agents	1.0	0.9	0.0	0.0	168	166	0	2	174	176	0	69	3,375	586,320	327	13.3	3,487
Analgesics and Anesthetics	1.0	0.2	0.0	0.7	56	27	7	22	55	127	149	29	15,163	838,380	1,410	57.5	15,042
Neuromuscular Agents	1.4	0.4	0.1	1.0	100	50	6	45	70	140	71	45	20,254	1,419,759	1,298	52.9	14,166
Nutritional Products	1.0	0.1	0.0	0.9	26	2	0	23	26	32	21	26	12,446	328,430	1,190	48.5	12,730
Hematological Agents	1.1	0.5	0.1	0.5	123	111	3	10	116	242	25	19	10,085	1,170,270	923	37.6	9,483
Topical Products	0.7	0.3	0.1	0.3	38	25	3	10	56	81	60	32	11,019	619,602	1,492	60.8	16,197
Miscellaneous Products	0.4	0.0	0.0	0.3	80	5	0	75	218	135	222	227	614	134,083	163	6.6	1,672
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	14	0	0	0	44	0	0	0	647	28,455	179	7.3	2,011
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	217,064	16,437,546	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

In Louisiana, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Users

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were

in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP-10 DRUG GROUPa, b, c, d NONDUAL BENEFICIARIES, LOUISIANA, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$3,723,607	1,759	71.7	19,684	0.9	\$222	\$189
ANTICONVULSANT	1,181,096	1,364	55.6	15,054	0.9	83	78
ULCER DRUGS	1,159,461	1,437	58.6	15,279	0.7	103	76
ANTIDEPRESSANTS	886,548	1,601	65.3	17,451	0.8	63	51
ANTIDIABETIC	749,804	1,406	57.3	14,959	0.8	61	50
HEMATOPOIETIC AGENTS	598,207	848	34.6	8,849	0.7	102	68
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	586,320	406	16.6	4,344	0.8	174	135
ANTIVIRAL	530,689	176	7.2	1,829	0.6	464	290
ANTIHYPERLIPIDEMIC	504,750	626	25.5	6,806	0.8	96	74
ANTIHYPERTENSIVE	479,198	1,429	58.3	15,106	0.8	40	32
Total	10,399,680	11,052		119,361	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinious/serient and action of the control of the con

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

TABLE ND.10A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	All Top 10	Drug Groups		ANTIPS	YCHOTICS				ANTICO	NVULSANT		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	
All	96,220	\$10,399,680	1,759	71.7	19,684	0.9	\$189	1,364	55.6	15,054	0.9	\$79
Female												
All Females	52,796	5,666,445	991	79.9	11,111	0.9	192	705	56.9	7,843	0.9	80
Female, Disabled												
All Ages	42,257	4,777,276	792	86.5	8,980	0.9	208	601	65.6	6,711	1.0	82
64 or younger	42,113	4,753,734	787	86.9	8,938	0.9	208	598	66.0	6,684	1.0	82
65-74	144	23,542	5	50.0	42	0.8	307	3	30.0	27	0.7	91
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	10,539	889,169	199	61.4	2,131	0.8	121	104	32.1	1,132	0.9	66
64 or younger	82	8,964	1	50.0	12	0.7	239	2	100.0	24	1.2	43
65-74	4,646	448,235	104	95.4	1,147	0.8	149	60	55.0	675	0.9	76
75-84	3,011	236,494	52	50.0	546	0.8	113	22	21.2	227	0.8	55
85 and older	2,800	195,476	42	38.5	426	0.6	54	20	18.3	206	1.0	50
Male												
All Males	43,334	4,724,900	765	63.4	8,555	0.9	186	657	54.5	7,198	0.9	77
Male, Disabled												
All Ages	34,193	3,942,522	616	66.3	6,935	0.9	200	572	61.6	6,269	1.0	79
64 or younger	34,105	3,930,674	614	66.5	6,922	0.9	200	571	61.9	6,268	1.0	79
65-74	88	11,848	2	33.3	13	1.1	497	1	16.7	1	1.0	92
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	9,141	782,378	149	53.8	1,620	0.8	126	85	30.7	929	0.9	64
64 or younger	22	1,738	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	4,269	373,446	67	65.7	765	1.0	161	47	46.1	508	1.0	81
75-84	2,834	227,648	56	65.9	583	0.7	93	26	30.6	306	0.7	46
85 and older	2,016	179,546	26	29.2	272	0.7	98	12	13.5	115	0.9	38
Unknown	90	8,335	3	42.9	18	0.3	73	2	28.6	13	0.3	23

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters

Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s): BOE = basis of eligibility; CMS = Centers for Medicare & Medicard Services; MAX = Medicard Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicard reimbursement.

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, LOUISIANA, 2005

	ULCER DRUGS ANTIDEPRESSANTS ANTIDIABETIC														
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents		Mean Number of Rx	
All	1,437	58.6	15,279			1,601	65.3	17,451	0.8	\$51	1,406	57.3	14,959		
Female															
All Females	795	64.1	8,590	0.7	77	907	73.1	9,921	0.8	51	793	64.0	8,579	0.8	51
Female, Disable	ed														
All Ages	605	66.0	6,594	0.8	79	720	78.6	7,948	0.8	52	608	66.4	6,658	0.8	52
64 or younger	600	66.2	6,564	0.8	79	716	79.0	7,917	0.8	52	603	66.6	6,621	0.8	52
65-74	5	50.0	30	0.8	95	4	40.0	31	0.4	39	5	50.0	37	0.7	75
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	Eligibles														
All Ages	190	58.6	1,996	0.7	70	187	57.7	1,973	0.8	48	185	57.1	1,921	0.8	45
64 or younger	4	200.0	44	0.7	99	0	0.0	0	0.0	0	1	50.0	8	1.8	88
65-74	69	63.3	771	0.7	75	78	71.6	817	0.8	52	84	77.1	892	0.8	44
75-84	55	52.9	569	0.7	57	52	50.0	529	0.9	43	53	51.0	540	0.8	45
85 and older	62	56.9	612	0.7	73	57	52.3	627	0.8	47	47	43.1	481	0.8	47
Male															
All Males	641	53.2	6,679	0.7	75	692	57.4	7,524	0.8	51	611	50.7	6,368	0.8	49
Male, Disabled															
All Ages	505	54.4	5,212	0.7	72	518	55.8	5,671	0.8	50	486	52.3	5,038	0.8	52
64 or younger	504	54.6	5,200	0.7	72	515	55.8	5,656	0.8	50	484	52.4	5,025	0.8	51
65-74	1	16.7	12	0.8	100	3	50.0	15	0.7	58	2	33.3	13	1.0	152
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Elig	gibles														
All Ages	136	49.1	1,467	0.8	84	174	62.8	1,853	0.8	54	125	45.1	1,330	0.8	41
64 or younger	2	200.0	24	0.9	72	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	53	52.0	603	0.8	85	72	70.6	766	0.8	53	62	60.8	693	0.8	46
75-84	45	52.9	499	0.7	69	50	58.8	518	0.8	57	45	52.9	456	0.8	35
85 and older	36	40.4	341	0.8	105	52	58.4	569	0.8	53	18	20.2	181	0.9	
Unknown	1	14.3	10	0.7	7	2	28.6	6	0.3	14	2	28.6	12	1.0	37

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinibisherient and action of the control of the cont

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, LOUISIANA, 2005

		⊣ЕМАТОР С	DIETIC AGEN	ITS		MISC		HERAPEUT OLOGICAL	IC AND			ΔΝΊ	ΓIVIRAL		
		ILIVIATOR	JIL TIC AGEN	113			NEOK	JLOGICAL				AIN	IIVINAL		
Beneficiary Characteristics	Number of Users	Year Nursing Facility		Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents		Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents		Mean Number of Rx	
All	848	34.6	8,849	0.7	\$68	406	16.6	4,344	0.8	\$135	176	7.2	1,829	0.6	\$290
Female															
All Females	458	36.9	4,852	0.7	58	229	18.5	2,413	0.8	153	73	5.9	735	0.5	188
Female, Disable	ed														
All Ages	361	39.4	3,861	0.7	66	123	13.4	1,380	0.8	195	65	7.1	649	0.6	213
64 or younger	359	39.6	3,848	0.7	66	122	13.5	1,379	0.8	195	65	7.2	649	0.6	213
65-74	2	20.0	13	0.5	6	1	10.0	1	2.0	212	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	ligibles														
All Ages	97	29.9	991	0.7	29	106	32.7	1,033	0.8	97	8	2.5	86	0.1	4
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	29	26.6	306	0.7	11	25	22.9	270	0.8	100	2	1.8	24	0.1	4
75-84	26	25.0	273	0.7	46	38	36.5	380	0.8	102	4	3.8	48	0.1	5
85 and older	42	38.5	412	0.7	30	43	39.4	383	0.7	89	2	1.8	14	0.1	4
Male															
All Males	389	32.3	3,995	0.6	79	173	14.3	1,901	0.8	113	103	8.5	1,094	0.7	359
Male, Disabled															
All Ages	293	31.5	2,983	0.6	89	86	9.3	991	0.8	125	96	10.3	1,013	0.7	387
64 or younger	292	31.6	2,972	0.6	89	86	9.3	991	0.8	125	96	10.4	1,013	0.7	387
65-74	1	16.7	11	1.0	15	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Elig	jibles														
All Ages	96	34.7	1,012	0.7	50	87	31.4	910	0.8	99	7	2.5	81	0.1	3
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	34	33.3	371	0.6	23	25	24.5	276	0.9	110	4	3.9	48	0.1	3
75-84	38	44.7	429	0.7	58	28	32.9	275	0.8	88	1	1.2	9	0.1	2
85 and older	24	27.0		0.6		34	38.2	359	0.7		2	2.2	24	0.1	2
Unknown	1	14.3	2	0.5	52	4	57.1	30	0.9	126	0	0.0	0	0.0	0

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

In hulasing racinities for part of intellemental manufacture and train state in the activities.

A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, LOUISIANA, 2005

ANTIHYPERLIPIDEMIC

ANTIHYPERTENSIVE

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	626	25.5	6,806	0.8	\$74	1,429	58.3	15,106	0.8	\$32	2,453	25,268
Female												
All Females	324	26.1	3,544	0.8	76	737	59.4	7,812	0.8	32	1,240	12,999
Female, Disable	ed											
All Ages	256	27.9	2,842	0.8	76	568	62.0	6,077	0.8	33	916	9,774
64 or younger	256	28.3	2,842	0.8	76	564	62.3	6,053	0.8	33	906	9,722
65-74	0	0.0	0	0.0	0	4	40.0	24	0.9	46	10	52
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other E	ligibles											
All Ages	68	21.0	702	0.8	76	169	52.2	1,735	0.8	31	324	3,225
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	20
65-74	42	38.5	446	0.7	70	68	62.4	711	0.8	37	109	1,163
75-84	17	16.3	178	0.9	92	56	53.8	569	0.8	26	104	994
85 and older	9	8.3	78	0.9	78	45	41.3	455	0.8	27	109	1,048
Male												
All Males	300	24.9	3,250	0.7	72	688	57.0	7,260	0.8	31	1,206	12,224
Male, Disabled												
All Ages	234	25.2	2,581	0.7	73	521	56.1	5,494	0.8	31	929	9,438
64 or younger	233	25.2	2,570	0.7	73	517	56.0	5,465	0.8	31	923	9,401
65-74	1	16.7	11	0.4	49	4	66.7	29	0.9	19	6	37
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	jibles											
All Ages	66	23.8	669	0.8	68	167	60.3	1,766	0.8	31	277	2,786
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
65-74	28	27.5	314	0.7	65	79	77.5	870	0.8	30	102	1,120
75-84	21	24.7	220	0.9	73	48	56.5	504	0.8	29	85	823
85 and older	17	19.1	135	0.6	64	40	44.9	392	0.8	35	89	831
Unknown	2	28.6	12	0.6	66	4	57.1	34	0.7	43	7	45

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,617 beneficiaries who were in nursing facilities for part of their enrollment and their 15,622 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTICa,b LOUISIANA, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	\$ per	Total Part D Excluded Rx \$		Part D Excluded Rx \$ as a 'ercentage of All Nondual Rx \$	Total Number of Beneficiaries
All	229,708	23.5	0.7	687,576	\$16	\$15,272,180	\$22	2.8	979,374
Age									
5 and younger	69,930	25.8	0.5	138,916	9	2,544,050	18	3.1	270,532
6-14	63,823	19.3	0.4	121,826	9	2,962,147	24	2.4	330,286
15-20	32,052	18.8	0.4	64,462	9	1,544,159	24	2.5	170,407
21-44	38,101	25.5	1.1	164,628	25	3,711,142	23	3.0	149,679
45-64	24,385	43.8	3.3	185,178	75	4,191,712	23	2.7	55,647
65-74	708	48.5	4.3	6,324	118	171,799	27	3.8	1,460
75-84	423	50.4	4.4	3,700	100	83,612	23	3.5	840
85 and older	286	55.0	4.9	2,542	122	63,559	25	4.0	520
Unknown	0	0.0	0.0	0	0	0	0	0.0	3
Basis of Eligibility	С								
Aged	1,357	49.6	4.5	12,242	114	312,591	26	3.8	2,734
Disabled	47,652	36.3	2.3	305,654	58	7,592,226	25	2.6	131,416
Adults	29,845	22.3	0.7	92,727	14	1,908,271	21	3.6	134,065
Children	150,571	21.2	0.4	275,743	8	5,438,002	20	2.7	710,250
Unknown	283	31.1	1.3	1,210	23	21,090	17	0.6	909
Gender									
Female	136,349	24.9	0.8	436,461	18	9,821,477	23	3.1	548,637
Male	93,324	21.7	0.6	250,998	13	5,448,686	22	2.3	430,613
Unknown	35	28.2	0.9	117	16	2,017	17	2.8	124
Race									
White	97,973	27.9	0.9	325,236	21	7,279,580	22	2.8	350,708
African American	114,568	20.6	0.5	303,105	12	6,491,441	21	2.6	556,504
Other/unknown	17,167	23.8	0.8	59,235	21	1,501,159	25	3.0	72,162
Use of Nursing Fac	cilitiesd								
Entire year	1,770	72.2	10.2	24,980	232	568,781	23	3.5	2,453
Part year	1,204	74.5	7.2	11,603	181	292,890	25	3.6	1,617
None	226,734	23.2	0.7	650,993	15	14,410,509	22	2.7	975,304
Maintenance Assis	stance Status								
Cash	88,957	29.0	1.3	410,858	31	9,570,282	23	2.8	306,437
Medically needy	711	31.9	1.2	2,627	28	62,289	24	3.3	2,232
Poverty related	127,072	21.6	0.4	230,186	8	4,707,741	20	2.8	588,029
Other/unknown	12,968	15.7	0.5	43,905	11	931,868	21	2.5	82,676

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b} LOUISIANA, 2005

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.1	\$2	\$22	\$0	\$0	10,163,499
Age						
5 and younger	0.1	1	18	0	0	2,744,431
6-14	0.0	1	24	0	0	3,714,965
15-20	0.0	1	24	0	0	1,775,630
21-44	0.1	3	23	0	1	1,333,734
45-64	0.3	7	23	0	3	565,900
65-74	0.4	11	27	0	3	15,248
75-84	0.4	10	23	0	2	8,639
85 and older	0.5	13	25	0	2	4,944
Unknown	0.0	0	0	0	0	8
Basis of Eligibility ^c						
Aged	0.4	11	26	0	2	28,125
Disabled	0.2	5	25	0	2	1,429,559
Adults	0.1	2	21	0	1	1,106,185
Children	0.0	1	20	0	0	7,592,250
Unknown	0.2	3	17	0	1	7,380
Gender						
Female	0.1	2	23	0	0	5,590,380
Male	0.1	1	22	0	0	4,571,919
Unknown	0.1	2	17	0	0	1,200
Race						
White	0.1	2	22	0	1	3,514,632
African American	0.1	1	21	0	0	5,936,730
Other/unknown	0.1	2	25	0	1	712,137
Use of Nursing Faci	lities ^d					
Entire year	1.0	23	23	0	7	25,268
Part year	0.7	19	25	0	5	15,622
None	0.1	1	22	0	0	10,122,609
Maintenance Assist	ance Status					
Cash	0.1	3	23	0	1	3,243,152
Medically needy	0.1	3	24	0	1	22,820
Poverty related	0.0	1	20	0	0	6,226,821
Other/unknown	0.1	1	21	0	0	670,706

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,C}
LOUISIANA, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	281,648	\$54	\$15,272,180	100.0	687,576	\$22	100.0
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	5	89	444	0.0	10	44	0.0
Drugs for cosmetic purposes	0	0	0	0.0	0	0	0.0
Cough and cold medications	141,685	35	5,000,742	32.7	227,404	22	33.1
Vitamins and minerals	46,808	52	2,448,077	16.0	133,392	18	19.4
Non-prescription drugs	44,073	22	973,352	6.4	82,147	12	11.9
Barbiturates	3,232	78	252,963	1.7	25,409	10	3.7
Benzodiazepines	32,138	116	3,717,943	24.3	182,989	20	26.6
Other Part D Excl Rx Drugs	13,707	210	2,878,659	18.8	36,225	79	5.3

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who sused drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, LOUISIANA, 2005

			Number of			FICIARIES, LOUISIAN	Number of Benefit Months						
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	
All	979,374	2,734	131,416	134,065	710,250	909	10,163,499	28,125	1,429,559	1,106,185	7,592,250	7,380	
Age													
5 and younger	270,532	12	8,583	1	261,936	0	2,744,431	27	94,695	1	2,649,708	0	
6-14	330,286	8	20,348	18	309,912	0	3,714,965	16	234,888	96	3,479,965	0	
15-20	170,407	4	15,311	16,789	138,292	11	1,775,630	8	173,249	140,554	1,461,743	76	
21-44	149,679	14	38,426	110,831	104	304	1,333,734	27	416,613	914,010	811	2,273	
45-64	55,647	6	48,624	6,424	3	590	565,900	12	509,340	51,514	15	5,019	
65-74	1,460	1,331	124	1	0	4	15,248	14,454	774	8	0	12	
75-84	840	840	0	0	0	0	8,639	8,639	0	0	0	0	
85 and older	520	519	0	1	0	0	4,944	4,942	0	2	0	0	
Unknown	3	0	0	0	3	0	8	0	0	0	8	0	
Gender													
Female	548,637	1,735	65,827	125,643	354,523	909	5,590,380	17,962	721,522	1,045,005	3,798,511	7,380	
Male	430,613	983	65,586	8,416	355,628	0	4,571,919	10,023	708,012	61,142	3,792,742	0	
Unknown	124	16	3	6	99	0	1,200	140	25	38	997	0	
Race													
White	350,708	786	39,546	51,254	258,678	444	3,514,632	7,843	420,506	391,447	2,691,259	3,577	
African American	556,504	1,371	76,412	74,320	403,986	415	5,936,730	14,527	840,060	655,926	4,422,802	3,415	
Other/unknown	72,162	577	15,458	8,491	47,586	50	712,137	5,755	168,993	58,812	478,189	388	
Use of Nursing Facilities ^c													
Entire year	2,453	604	1,845	2	2	0	25,268	6,016	19,212	16	24	0	
Part year	1,617	272	1,335	5	4	1	15,622	2,758	12,769	38	48	9	
None	975,304	1,858	128,236	134,058	710,244	908	10,122,609	19,351	1,397,578	1,106,131	7,592,178	7,371	
Maintenance Assistance Statu	s												
Cash	306,437	1,840	125,124	72,775	106,698	0	3,243,152	20,280	1,373,640	676,667	1,172,565	0	
Medically needy	2,232	2	218	1,490	522	0	22,820	24	1,610	15,180	6,006	0	
Poverty related	588,029	27	48	51,147	535,898	909	6,226,821	305	483	330,692	5,887,961	7,380	
Other/unknown	82,676	865	6,026	8,653	67,132	0	670,706	7,516	53,826	83,646	525,718	0	
Managed Care (MC) Status													
Fee-for-service (FFS) all year	979,374	2,734	131,416	134,065	710,250	909	10,163,499	28,125	1,429,559	1,106,185	7,592,250	7,380	
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0	

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, LOUISIANA, 2005

Beneficiaries and Benefit Months in Cell J of Table 1 Included in Cell K of Table 1 Excluded from Cell K of Table 1 Number of Number of Number of Number of Number of Number of Beneficiaries Benefit Months Beneficiaries Benefit Months Beneficiaries Benefit Months ΑII 979,374 979,374 10,163,499 10,163,499 0 0 Fee-for-service (FFS) all year 979,374 0 0 10,163,499 979,374 10,163,499 FFS part year, with Rx claims 0 0 0 0 0 FFS part year, with no Rx claims 0 0 0 0 0 0 Managed care (MC) all year, with Rx claims 0 0 0 0 0 0 0 0 0 0 0 MC all year, with no Rx claims 0

Source: Data for this table are from the MAX 2005 file for Louisiana, released by CMS in 3/2009. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.